PMID: 2512049Jul 1, 1989Paper

Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia

Diagnostic Microbiology and Infectious Disease
N X Chin, H C Neu

Abstract

The effects of the combination of E-1040, a new cephalosporin, ceftazidime, cefpirome, or cefepime with tobramycin against 40 Pseudomonas aeruginosa and 16 P. cepacia isolates from cystic fibrosis patients were examined. Synergy fractional inhibitory concentration less than or equal to 0.5 was found against P. aeruginosa when tobramycin was combined with E-1040 32%, cefpirome 32%, cefepime 22%, and ceftazidime 22%. Fifty-two percent of isolates showed an additive response for E-1040, 60% for cefpirome, 45% cefepime, and 55% ceftazidime, p greater than 0.05. The differences were not statistically significant. Synergy was not more likely to be achieved if the isolates were susceptible or resistant to either the aminoglycoside or cephalosporin. None of the E-1040-resistant isolates, all of which were tobramycin-resistant, became susceptible when tested with an aminoglycoside, whereas 15 of 34 cefpirome-resistant, 13 of 30 cefepime-resistant, and seven of 14 ceftazidime-resistant isolates became susceptible. Synergy of aminoglycoside and the cephalosporins against P. cepacia was found for 25% with E-1040, 44% with cefpirome, 38% with cefepime, and 31% with ceftazidime. These differences were not statistically significant.

References

May 1, 1978·Antimicrobial Agents and Chemotherapy·H C Neu, K P Fu
Jul 1, 1987·The Pediatric Infectious Disease Journal·R PadoanA Giunta
Apr 1, 1986·The Journal of Antimicrobial Chemotherapy·H C NeuP Labthavikul
May 1, 1986·The Journal of Pediatrics·A Prince
May 1, 1985·Antimicrobial Agents and Chemotherapy·P C FuchsC Thornsberry
Nov 1, 1985·Reviews of Infectious Diseases·J D Allan, R C Moellering
Dec 1, 1971·The Journal of Infectious Diseases·V T Andriole
Feb 1, 1984·The Journal of Pediatrics·A IslesH Levison
Jun 1, 1984·Antimicrobial Agents and Chemotherapy·R N JonesA L Barry

❮ Previous
Next ❯

Citations

Jan 13, 2006·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B BalkeS Häussler
Nov 22, 1997·Diagnostic Microbiology and Infectious Disease·E J Giamarellos-BourboulisH Giamarellou
Aug 14, 2009·FEMS Microbiology Letters·Anthony M GeorgePeter G Middleton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.